Clene (CLNN) vs Laird Superfood (LSF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Laird Superfood (LSF) has outperformed Clene (CLNN) over the past year, losing 45.7% versus a loss of 58.8%. Over five years, LSF leads with a -82.4% price change compared with -96.9% for CLNN. Clene is the larger company by market cap ($55.2 million vs $34.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | LSF |
|---|---|---|
| Share price | $3.88 | $3.08 |
| Market cap | $55.15M | $34.47M |
| 1-day change | -1.02% | -1.28% |
| YTD return | -33.90% | +38.74% |
| 1-year return | -58.81% | -45.68% |
| 5-year return | -96.86% | -82.41% |
| EPS (TTM) | $-3.52 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.50 | $5.85 |
| 52-week low | $3.25 | $1.96 |
| Distance from 52-week high | -71.26% | -47.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +729.90% | +132.79% |
| Average volume | 100.21K | 33.42K |
| Shares outstanding | 14.21M | 11.19M |
| Employees | 76 | 26 |
| Sector | Health Care | Consumer Staples |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSF has outperformed CLNN by 13.1 percentage points over the past year.
- The two companies sit in different sectors: Clene in Health Care and Laird Superfood in Consumer Staples.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Laird Superfood
LSF stock →Laird Superfood, Inc. manufactures and markets plant-based natural and functional food in the United States.
Consumer Staples · Packaged Foods · 26 employees
CLNN vs LSF FAQ
Which is bigger, Clene or Laird Superfood?
Clene (CLNN) is larger, with a market capitalization of $55.15M compared with $34.47M for Laird Superfood (LSF).
Which stock has performed better over the past year, CLNN or LSF?
LSF returned -45.68% over the past 12 months, compared with -58.81% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Laird Superfood in the same industry?
No. Clene is in the Health Care sector, while Laird Superfood is in Consumer Staples.